Moderna sees Taiwan as a crucial site for clinical trials necessary for refining its mRNA technology, and will include it as a site for its multicenter trials, said Patrick Bergstedt, a senior vice president of Moderna, on Tuesday during his first visit to the country.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Culture
Indonesian diaspora celebrates Kartini Day in Taipei
04/20/2025 06:35 PM - Culture
Nymphia Wind crowns new RuPaul's Drag Race queen in glorious return
04/20/2025 05:04 PM - Business
TSMC forecasts healthy growth amid foundry sector recovery
04/20/2025 05:00 PM - Politics
Ex-NTU head warns Taiwan faces risks from both China and the U.S.
04/20/2025 04:30 PM - Business
Kaohsiung concert economy generates NT$5.7 billion in revenues in 2024
04/20/2025 04:10 PM